Pilot pharmacokinetic study of human immunodeficiency virus-infected patients receiving tenofovir disoproxil fumarate (TDF): Investigation of systemic and intracellular interactions between TDF and abacavir, lamivudine, or lopinavir-ritonavir

Antimicrobial Agents and Chemotherapy

Volumn 53, Issue 5, 2009, Pages 1937-1943

  Pruvost, Alain ^a   Negredo, Eugènia ^b   Théodoro, Frédéric ^a   Puig, Jordi ^b   Levi, Mikaël ^a,c   Ayen, Rafaela ^b   Grassi, Jacques ^a   Clotet, Bonaventura ^b  

^a SERVICE DE CHIMIE BIOORGANIQUE ET DE MARQUAGE   (France)

^b HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

^c SPI BIO   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; CARBOVIR; LAMIVUDINE; LOPINAVIR PLUS RITONAVIR; NEVIRAPINE; TENOFOVIR DISOPROXIL;

ADULT; AREA UNDER THE CURVE; ARTICLE; CD4 LYMPHOCYTE COUNT; CLINICAL ARTICLE; CROSS-SECTIONAL STUDY; DRUG HALF LIFE; DRUG METABOLISM; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIQUID CHROMATOGRAPHY; LONGITUDINAL STUDY; MALE; MAXIMUM PLASMA CONCENTRATION; PERIPHERAL BLOOD MONONUCLEAR CELL; PILOT STUDY; PRIORITY JOURNAL; SEX DIFFERENCE; STATISTICAL ANALYSIS; TANDEM MASS SPECTROMETRY; VIRUS INHIBITION; VIRUS LOAD; VIRUS SUPPRESSION;

EID: 66149147423     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01064-08     Document Type: Article

References (51)

1. Anderson, P. L., T. N. Kakuda, S. Kawle, and C. V. Fletcher. 2003. Antiviral dynamics and sex differences of zidovudine and lamivudine triphosphate concentrations in HIV-infected individuals. AIDS 17:2159-2168. (Pubitemid 37338889)
2. Barreiro, P., T. Garcia-Benayas, A. Rendon, S. Rodriguez-Novoa, and V. Soriano. 2004. Combinations of nucleoside/nucleotide analogues for HIV therapy. AIDS Rev. 6:234-243. (Pubitemid 40227885)
3. Barrios, A., A. Rendon, E. Negredo, P. Barreiro, T. Garcia-Benayas, P. Labarga, J. Santos, P. Domingo, M. Sanchez-Conde, I. Maida, L. Martin-Carbonero, M. Nunez, F. Blanco, B. Clotet, M. A. Sambeat, P. Gil, J. Gonzalez-Lahoz, D. Cooper, and V. Soriano. 2005. Paradoxical CD4+ T-cell decline in HIV-infected patients with complete virus suppression taking tenofovir and didanosine. AIDS 19:569-575. (Pubitemid 40543979)
4. Becher, F., A. Pruvost, C. Goujard, C. Guerreiro, J. F. Delfraissy, J. Grassi, and H. Benech. 2002. Improved method for the simultaneous determination of d4T, 3TC and ddI intracellular phosphorylated anabolites in human peripheral- blood mononuclear cells using high-performance liquid chromatography/tandem mass spectrometry. Rapid Commun. Mass Spectrom. 16:555-565. (Pubitemid 34205047)
5. Benech, H., F. Theodoro, A. Herbet, N. Page, D. Schlemmer, A. Pruvost, J. Grassi, and J. R. Deverre. 2004. Peripheral blood mononuclear cell counting using a DNA-detection-based method. Anal. Biochem. 330:172-174. (Pubitemid 38746990)
6. Blanchard, J. N., M. Wohlfeiler, A. Canas, K. King, and J. T. Lonergan. 2003. Pancreatitis with didanosine and tenofovir disoproxil fumarate. Clin. Infect. Dis. 37:e57-e62. (Corrected.)
7. Chandler, B., L. Almond, J. Ford, A. Owen, P. Hoggard, S. Khoo, and D. Back. 2003. The effects of protease inhibitors and nonnucleoside reverse transcriptase inhibitors on p-glycoprotein expression in peripheral blood mononuclear cells in vitro. J. Acquir. Immune Defic. Syndr. 33:551-556. (Pubitemid 36975841)
8. Delaney, W. E., IV, A. S. Ray, H. Yang, X. Qi, S. Xiong, Y. Zhu, and M. D. Miller. 2006. Intracellular metabolism and in vitro activity of tenofovir against hepatitis B virus. Antimicrob. Agents Chemother. 50:2471-2477. (Pubitemid 43993188)
9. Eron, J., Jr., P. Yeni, J. Gathe, Jr., V. Estrada, E. DeJesus, S. Staszewski, P. Lackey, C. Katlama, B. Young, L. Yau, D. Sutherland-Phillips, P. Wannamaker, C. Vavro, L. Patel, J. Yeo, and M. Shaefer. 2006. The KLEAN study of fosamprenavir-ritonavir versus lopinavir-ritonavir, each in combination with abacavir-lamivudine, for initial treatment of HIV infection over 48 weeks: a randomised non-inferiority trial. Lancet 368:476-482. (Pubitemid 44160731)
10. Fichtenbaum, C. J., J. G. Gerber, S. L. Rosenkranz, Y. Segal, J. A. Aberg, T. Blaschke, B. Alston, F. Fang, B. Kosel, and F. Aweeka. 2002. Pharmacokinetic interactions between protease inhibitors and statins in HIV seronegative volunteers: ACTG study A5047. AIDS 16:569-577. (Pubitemid 34218852)
11. Flaherty, J., B. Kearney, J. Wolf, J. Sayre, and D. Coakley. 2001. A multiple-dose, randomized, crossover, drug interaction study between tenofovir DF and efavirenz, indinavir, or lopinavir/ritonavir, abstr. 336. Abstr. 1st Int. AIDS Soc. Conf. HIV Pathogenesis Treatment.
12. Gallant, J. E., A. E. Rodriguez, W. G. Weinberg, B. Young, D. S. Berger, M. L. Lim, Q. Liao, L. Ross, J. Johnson, and M. S. Shaefer. 2005. Early virologic nonresponse to tenofovir, abacavir, and lamivudine in HIV-infected antiretroviral-naive subjects. J. Infect. Dis. 192:1921-1930. (Pubitemid 41681890)
13. Harris, M., D. Back, S. Kewn, S. Jutha, R. Marina, and J. S. Montaner. 2002. Intracellular carbovir triphosphate levels in patients taking abacavir once a day. AIDS 16:1196-1197. (Pubitemid 34533866)
14. Havlir, D. V., R. D. Schrier, F. J. Torriani, K. Chervenak, J. Y. Hwang, and W. H. Boom. 2000. Effect of potent antiretroviral therapy on immune responses to Mycobacterium avium in human immunodeficiency virus-infected subjects. J. Infect. Dis. 182:1658-1663.
15. Hawkins, T., W. Veikley, R. L. St. Claire III, B. Guyer, N. Clark, and B. P. Kearney. 2005. Intracellular pharmacokinetics of tenofovir diphosphate, carbovir triphosphate, and lamivudine triphosphate in patients receiving triple-nucleoside regimens. J. Acquir. Immune Defic. Syndr. 39:406-411. (Pubitemid 41003784)
16. Henneré, G., F. Becher, A. Pruvost, C. Goujard, J. Grassi, and H. Benech. 2003. Liquid chromatography-tandem mass spectrometry assays for intracellular deoxyribonucleotide triphosphate competitors of nucleoside antiretrovirals. J. Chromatogr. B 789:273-281.
17. Hoggard, P. G., S. Kewn, M. G. Barry, S. H. Khoo, and D. J. Back. 1997. Effects of drugs on 2′,3′-dideoxy-2′,3′- didehydrothymidine phosphorylation in vitro. Antimicrob. Agents Chemother. 41:1231-1236. (Pubitemid 27231419)
18. Huisman, M. T., J. W. Smit, K. M. Crommentuyn, N. Zelcer, H. R. Wiltshire, J. H. Beijnen, and A. H. Schinkel. 2002. Multidrug resistance protein 2 (MRP2) transports HIV protease inhibitors, and transport can be enhanced by other drugs. AIDS 16:2295-2301. (Pubitemid 35449015)
19. Huisman, M. T., J. W. Smit, H. R. Wiltshire, R. M. Hoetelmans, J. H. Beijnen, and A. H. Schinkel. 2001. P-glycoprotein limits oral availability, brain, and fetal penetration of saquinavir even with high doses of ritonavir. Mol. Pharmacol. 59:806-813. (Pubitemid 32274009)
20. Johnson, M. A., J. C. Gathe, Jr., D. Podzamczer, J. M. Molina, C. T. Naylor, Y. L. Chiu, M. S. King, T. J. Podsadecki, G. J. Hanna, and S. C. Brun. 2006. A once-daily lopinavir/ritonavir-based regimen provides noninferior antiviral activity compared with a twice-daily regimen. J. Acquir. Immune Defic. Syndr. 43:153-160. (Pubitemid 44454808)
21. Kearney, B. P., E. Isaacson, J. Sayre, R. Ebrahami, and A. K. Cheng. 2003. The pharmacokinetics of abacavir, a purine nucleoside analogue, are not affected by tenofovir DF, abstr. A-1615. Abstr. 43rd Intersci. Conf. Antimicrob. Agents Chemother.
22. Kearney, B. P., A. Mathias, A. Mittan, J. Sayre, R. Ebrahimi, and A. K. Cheng. 2006. Pharmacokinetics and safety of tenofovir disoproxil fumarate on coadministration with lopinavir/ritonavir. J. Acquir. Immune Defic. Syndr. 43:278-283. (Pubitemid 44674007)
23. Kearney, B. P., J. R. Sayre, J. F. Flaherty, S. S. Chen, S. Kaul, and A. K. Cheng. 2005. Drug-drug and drug-food interactions between tenofovir disoproxil fumarate and didanosine. J. Clin. Pharmacol. 45:1360-1367. (Pubitemid 41642438)
24. Kewn, S., G. J. Veal, P. G. Hoggard, M. G. Barry, and D. J. Back. 1997. Lamivudine (3TC) phosphorylation and drug interactions in vitro. Biochem. Pharmacol. 54:589-595. (Pubitemid 27404693)
25. Kiser, J., M. Carten, C. Aquilante, P. Anderson, P. Wolfe, T. King, T. Delahunty, L. Bushman, and C. Fletcher. 2008. The effect of lopinavir/ritonavir on the renal clearance of tenofovir in HIV-infected patients. Clin. Pharmacol. Ther. 83:265-272.
26. Lee, C. G., M. M. Gottesman, C. O. Cardarelli, M. Ramachandra, K. T. Jeang, S. V. Ambudkar, I. Pastan, and S. Dey. 1998. HIV-1 protease inhibitors are substrates for the MDR1 multidrug transporter. Biochemistry 37:3594-3601. (Pubitemid 28162914)
27. Levi, M., and A. Pruvost. 2006. Sensitive HPLC-ESI-MS/MS method for the simultaneous quantitative determination of abacavir, lamivudine and tenofovir in human plasma, abstr. 69. Abstr. 7th Int. Workshop Clin. Pharmacol. HIV Ther.
28. Moyle, G., C. Fletcher, C. Higgs, I. Song, Y. Lou, J. Lin, G. Yuen, E. Guerini, P. Hay, and M. Boffito. 2007. An open-label, two-period, crossover, pharmacokinetic (PK) study of abacavir (ABC) and its intracellular anabolite carbovir triphosphate (CBV-TP) following 600 mg once-daily and 300 mg twice-daily administration of ABC in HIV-infected subjects, abstr. 13. Abstr. 8th Int. Workshop Clin. Pharmacol. HIV Ther.
29. Murphy, M. D., M. O'Hearn, and S. Chou. 2003. Fatal lactic acidosis and acute renal failure after addition of tenofovir to an antiretroviral regimen containing didanosine. Clin. Infect. Dis. 36:1082-1085. (Pubitemid 36513297)
30. Negredo, E., J. Molto, D. Burger, P. Viciana, E. Ribera, R. Paredes, M. Juan, L. Ruiz, J. Puig, A. Pruvost, J. Grassi, E. Masmitja, and B. Clotet. 2004. Unexpected CD4 cell count decline in patients receiving didanosine and tenofovir-based regimens despite undetectable viral load. AIDS 18:459-463. (Pubitemid 38365873)
31. Ouellet, D., A. Hsu, J. Qian, C. S. Locke, C. J. Eason, J. H. Cavanaugh, J. M. Leonard, and G. R. Granneman. 1998. Effect of ritonavir on the pharmacokinetics of ethinyl oestradiol in healthy female volunteers. Br. J. Clin. Pharmacol. 46:111-116. (Pubitemid 28342780)
32. Pecora Fulco, P., and M. A. Kirian. 2003. Effect of tenofovir on didanosine absorption in patients with HIV. Ann. Pharmacother. 37:1325-1328. (Pubitemid 37040226)
33. Perloff, M. D., L. L. Von Moltke, J. E. Marchand, and D. J. Greenblatt. 2001. Ritonavir induces P-glycoprotein expression, multidrug resistance-associated protein (MRP1) expression, and drug transporter-mediated activity in a human intestinal cell line. J. Pharm. Sci. 90:1829-1837. (Pubitemid 33062604)
34. Pruvost, A., E. Negredo, H. Benech, B. Clotet, and J. Grassi. 2005. Possible interaction between tenofovir and boosted lopinavir; analysis at the intracellular level in HIV infected patients, abstr. 34. Abstr. 6th Int. Workshop Clin. Pharmacol. HIV Ther.
35. Pruvost, A., E. Negredo, H. Benech, F. Theodoro, J. Puig, E. Grau, E. Garcia, J. Molto, J. Grassi, and B. Clotet. 2005. Measurement of intracellular didanosine and tenofovir phosphorylated metabolites and possible interaction of the two drugs in human immunodeficiency virus-infected patients. Antimicrob. Agents Chemother. 49:1907-1914. (Pubitemid 40631606)
36. Pruvost, A., F. Theodoro, L. Agrofoglio, E. Negredo, and H. Benech. 2008. Specificity enhancement with LC-positive ESI-MS/MS for the measurement of nucleotides: application to the quantitative determination of carbovir triphosphate, lamivudine triphosphate and tenofovir diphosphate in human peripheral blood mononuclear cells. J. Mass Spectrom. 43:224-233.
37. Ray, A. S. 2005. Intracellular interactions between nucleos(t)ide inhibitors of HIV reverse transcriptase. AIDS Rev. 7:113-125. (Pubitemid 41079022)
38. Ray, A. S., F. Myrick, J. E. Vela, L. Y. Olson, E. J. Eisenberg, K. Borroto- Esodo, M. D. Miller, and A. Fridland. 2005. Lack of a metabolic and antiviral drug interaction between tenofovir, abacavir and lamivudine. Antivir. Ther. 10:451-457. (Pubitemid 41151023)
39. Ray, A. S., L. Olson, and A. Fridland. 2004. Role of purine nucleoside phosphorylase in interactions between 2′,3′-dideoxyinosine and allopurinol, ganciclovir, or tenofovir. Antimicrob. Agents Chemother. 48:1089-1095. (Pubitemid 38405459)
40. Rollot, F., E. M. Nazal, L. Chauvelot-Moachon, C. Kelaidi, N. Daniel, M. Saba, S. Abad, and P. Blanche. 2003. Tenofovir-related Fanconi syndrome with nephrogenic diabetes insipidus in a patient with acquired immunodeficiency syndrome: the role of lopinavir-ritonavir-didanosine. Clin. Infect. Dis. 37:e174-e176.
41. + peripheral blood T cells following treatment with tenofovir +/- abacavir +/- lamivudine. Abstr. XV Int. HIV Drug Resist. Workshop, abstr. 146.
42. Stretcher, B. N., A. J. Pesce, P. T. Frame, and D. S. Stein. 1994. Pharmacokinetics of zidovudine phosphorylation in peripheral blood mononuclear cells from patients infected with human immunodeficiency virus. Antimicrob. Agents Chemother. 38:1541-1547. (Pubitemid 24203566)
43. Tong, L., T. K. Phan, K. L. Robinson, D. Babusis, R. Strab, S. Bhoopathy, I. J. Hidalgo, G. R. Rhodes, and A. S. Ray. 2007. Effects of human immunodeficiency virus protease inhibitors on the intestinal absorption of tenofovir disoproxil fumarate in vitro. Antimicrob. Agents Chemother. 51:3498-3504. (Pubitemid 47519335)
44. Tseng, A., and D. Fletcher. 1998. Interaction between ritonavir and levothyroxine. AIDS 12:2235-2236. (Pubitemid 28495284)
45. van der Lee, M. J., L. Dawood, H. J. ter Hofstede, M. J. de Graaff-Teulen, E. W. van Ewijk-Beneken Kolmer, N. Caliskan-Yassen, P. P. Koopmans, and D. M. Burger. 2006. Lopinavir/ritonavir reduces lamotrigine plasma concentrations in healthy subjects. Clin. Pharmacol. Ther. 80:159-168.
46. Vela, J. E., M. D. Miller, G. R. Rhodes, and A. S. Ray. 2005. Effect of tenofovir in combination with other anti-HIV NRTIs on intracellular nucleotide pools, poster H-1901. Abstr. 45th Intersci. Conf. Antimicrob. Agents Chemother.
47. Vishnuvardhan, D., L. L. Moltke, C. Richert, and D. J. Greenblatt. 2003. Lopinavir: acute exposure inhibits P-glycoprotein, extended exposure induces P-glycoprotein. AIDS 17:1092-1094. (Pubitemid 36549726)
48. Viswanathan, C. T., S. Bansal, B. Booth, A. J. DeStefano, M. J. Rose, J. Sailstad, V. P. Shah, J. P. Skelly, P. G. Swann, and R. Weiner. 2007. Quantitative bioanalytical methods validation and implementation: best practices for chromatographic and ligand binding assays. Pharm. Res. 24:1962-1973. (Pubitemid 47389236)
49. Wang, L. H., G. E. Chittick, and J. A. McDowell. 1999. Single-dose pharmacokinetics and safety of abacavir (1592U89), zidovudine, and lamivudine administered alone and in combination in adults with human immunodeficiency virus infection. Antimicrob. Agents Chemother. 43:1708-1715. (Pubitemid 29331252)
50. Waters, L. J., G. Moyle, S. Bonora, A. D'Avolio, L. Else, S. Mandalia, A. Pozniak, M. Nelson, B. Gazzard, D. Back, and M. Boffito. 2007. Abacavir plasma pharmacokinetics in the absence and presence of atazanavir/ritonavir or lopinavir/ritonavir and vice versa in HIV-infected patients. Antivir. Ther. 12:825-830. (Pubitemid 47235497)
51. Yeni, P. G., S. M. Hammer, M. S. Hirsch, M. S. Saag, M. Schechter, C. C. Carpenter, M. A. Fischl, J. M. Gatell, B. G. Gazzard, D. M. Jacobsen, D. A. Katzenstein, J. S. Montaner, D. D. Richman, R. T. Schooley, M. A. Thompson, S. Vella, and P. A. Volberding. 2004. Treatment for adult HIV infection: 2004 recommendations of the International AIDS Society - USA Panel. JAMA 292:251-265. (Pubitemid 38918003)